Solid Biosciences has received FDA clearance for its Investigational New Drug (IND) application for SGT-212, a gene therapy designed to treat Friedreich’s ataxia (FA). SGT-212 is unique because it uses a dual route of administration – intravenous infusion and direct infusion into the cerebellum – to deliver a full-length frataxin gene. This approach aims to address both the neurological and cardiac manifestations of FA, a debilitating and life-shortening genetic disorder.
This IND clearance is a critical step for FA patients currently lacking effective treatment options. SGT-212’s targeted approach addresses a significant unmet need by aiming to treat both the debilitating neurological symptoms, such as loss of coordination and speech difficulties, and the life-threatening cardiac issues that characterize FA. The dual delivery method is a novel strategy designed to overcome the challenges in treating this complex multisystem disease, specifically addressing the need for precise frataxin protein expression levels in the cerebellum and heart.
SGT-212 utilizes an AAV vector to deliver the frataxin gene. Preclinical studies have shown the therapy successfully transduced target tissues, restored neurological function, and reversed cardiac implications in mice. A Phase 1b clinical trial is expected to begin in the second half of 2025. This trial will be an open-label, dose-finding study enrolling both ambulatory and non-ambulatory adult FA patients. The trial will assess the safety and tolerability of SGT-212 and will involve a five-year follow-up period.
The IND clearance for SGT-212 represents a significant advancement in the field of gene therapy for FA. The upcoming clinical trial will provide crucial data regarding the safety and efficacy of this novel dual-administration approach. Positive results from this trial could pave the way for a new treatment paradigm for FA, potentially offering hope for patients suffering from this devastating disease.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
